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Predominantly myalgic phenotype caused
by the c.3466G.A p.A1156T mutation
in SCN4A gene
ABSTRACT
Objective: To characterize the clinical phenotype in patients with p.A1156T sodium channel
mutation.
Methods: Twenty-nine Finnish patients identified with the c.3466G.A p.A1156Tmutation in the
SCN4A gene were extensively examined. In a subsequent study, 63 patients with similar myalgic
phenotype and with negative results in myotonic dystrophy type 2 genetic screening (DM2-neg
group) and 93 patients diagnosed with fibromyalgia were screened for the mutation. Functional
consequences of the p.A1156T mutation were studied in HEK293 cells with whole-cell patch
clamp.
Results: The main clinical manifestation in p.A1156T patients was not myotonia or periodic paral-
ysis but exercise- and cold-induced muscle cramps, muscle stiffness, and myalgia. EMGmyotonic
discharges were detected in most but not all. Electrophysiologic compound muscle action poten-
tials exercise test showed variable results. The p.A1156T mutation was identified in one patient
in the DM2-neg group but not in the fibromyalgia group, making a total of 30 patients so far iden-
tified. Functional studies of the p.A1156T mutation showed mild attenuation of channel fast
inactivation.
Conclusions: The unspecific symptoms of myalgia stiffness and exercise intolerance without clin-
ical myotonia or periodic paralysis in p.A1156T patients make the diagnosis challenging. The
symptoms of milder SCN4A mutations may be confused with other similar myalgic syndromes,
including fibromyalgia and myotonic dystrophy type 2. Neurology® 2017;88:1520–1527
GLOSSARY
CK 5 creatine kinase; CMAP 5 compound muscle action potentials; DM2 5 myotonic dystrophy type 2; HyperPP 5 hyper-
kalemic periodic paralysis; PMC 5 paramyotonia congenita.
Mutations in the sodium channel gene SCN4A encoding the Nav1.4 voltage-gated sodium
channel are well-known causes of the skeletal muscle channelopathies: paramyotonia congenita
(PMC), other forms of myotonia, and periodic paralyses (hyperkalemic periodic paralysis [Hy-
perPP], normokalemic, and hypokalemic periodic paralysis). To date,.40 dominant mutations
in SCN4A have been reported to cause variable phenotypes, depending on the type and location
of the mutations.1,2 In addition, rare recessive SCN4A mutations have been associated with
congenital myasthenia or congenital myopathy.3,4 The type of channel defect and the degree of
depolarization account for clinical symptoms; membrane hyperexcitability causes myotonia,
increased membrane depolarization, and inexcitability, leading to paralysis,5–7 while membrane
hypoexcitability underlies myasthenias and myopathies.
The c.3466G.A p.A1156T mutation in the SCN4A gene was originally reported in a family
of Finnish origin with incomplete penetrance. The phenotype varied and consisted of features of
HyperPP, PMC, and myotonia.8 We now report clinical and electrophysiologic findings in 30
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Finnish patients with the c.3466G.A p.
A1156T mutation, including 1 patient found
in the screening study. Their unspecific, pre-
dominantly myalgic phenotype was very con-
sistent in all patients lacking most of the other
typical features of SCN4A channelopathies.
The relatively modest gain in the function of
p.A1156T channel may explain this unusual
clinical phenotype often lacking myotonic
findings.
METHODS p.A1156T patients. We identified 29 Finnish
patients from 18 different families who had similar clinical phe-
notype and a confirmed c.3466G.A p.A1156T mutation in
SCN4A (table e-1 at Neurology.org). The index family (F1)
consisted of 7 affected members who had muscle stiffness and
myalgia (figure 1). Three of them had an earlier diagnosis of
congenital myotonia based on myotonic discharges observed on
EMG examination, but when genetic testing became available,
the genetic defects in the chloride channel gene CLCN1 could be
ruled out. Four families (F1–F4) had several affected members in
2 or 3 generations (figure 1); others were single patients, but
many of them had family members with similar muscle symp-
toms. The patients underwent clinical examinations by neurol-
ogists, including manual muscle strength evaluation, assessment
of clinical myotonia (grip myotonia, percussion myotonia, and
eyelid myotonia) and paramyotonia (repeated action myotonia),
creatine kinase (CK) levels, and electrophysiologic studies.
Muscle biopsy was available in 12 patients. Three patients were
also examined by muscle MRI.
Screening study of myotonic dystrophy type 2–negative
and fibromyalgia patients. Sixty-three patients who were ear-
lier suspected to have myotonic dystrophy type 2 (DM2) on the
basis of exercise-induced myalgia, stiffness, and EMG findings
and who had had negative results in the genetic testing for the
CNBP repeat expansion mutation causing DM2 were included in
the screening study (DM2-neg group). They had normal or
Figure 1 Pedigree of the families
*DNA available.
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slightly elevated CK levels (up to 2 times the upper normal limit),
no evidence of fixed muscle weakness, and minor findings on
muscle biopsy, i.e., small 2A fibers or increased amount of
internal nuclei. On EMG, they had either increased insertional
activity or some myotonic discharges. In addition, 93 patients
with a diagnosis of fibromyalgia but no suspicion of myopathy
were screened for SCN4A exon 19 mutations.
Electrophysiologic studies. Standard neurography and EMG
investigation was performed in 25 patients with p.A1156T.
At minimum, 2 motor and 2 sensory nerve conduction studies
were performed, and both proximal and distal muscle groups
investigated from at least 1 upper and 1 lower limb. Compound
muscle action potentials (CMAP) exercise test was carried out in
14 patients. A Fournier protocol was used9,10 consisting of short
(10–12 seconds) and long (5 minutes) exercise tests. CMAP were
evoked by supramaximal nerve stimulation. Tested muscles were
the abductor digiti minimi and extensor digitorum brevis.
Muscle biopsy. Routine diagnostic histologic and histochemical
stainings were performed in 12 patients. In addition, chloride
channel CLC-1 immunohistochemistry was performed in 4
samples with a published method.11
Genetic studies. Genomic DNA was extracted from leukocytes
by standard methods. At the beginning of the investigations, 13
patients were tested for congenital myotonia (CLCN1, at least
the 3 most common mutations in Finland), 14 for DM2 (CNBP
repeat expansion mutation), and 2 for DM1 (DMPK repeat
expansion mutation). There was a heterozygous known recessive
mutation in CLCN1 gene in 2 patients, whereas other results
were negative. For all patients but one (P13), the whole coding
sequence of exon 19 of SCN4A was screened. The region studied
was amplified by PCR and directly sequenced with the Big-Dye
Terminator version 3.1 kit on an ABI3130xl automatic DNA
sequencer system (Applied Biosystems, Foster City, CA). Se-
quences were analyzed with Sequencher 5.1 software (Gene
Codes Corporation, Ann Arbor, MI). The primers used are
available on request. For P13, the genetic analysis was performed
using targeted next-generation sequencing as previously
described12 with version 2 of the MYOcap gene panel that is
targeted to the exons of 236 genes known or predicted to cause
muscular dystrophy or myopathy.
Mutagenesis, in vitro transcription, HEK293 cell
transfection, and whole-cell patch clamp. The human
SCN4A expression clone was a gift from S.C. Cannon (University
of Texas Southwestern Medical Center, Dallas). Site-directed
mutagenesis was performed with the QuikChange kit (Stra-
tagene) and confirmed by sequencing the entire insert. HEK293
cells were transfected with 0.5 mg wild-type or mutant plasmid
together with 50 ng plasmid coding for cop-GFP with Lip-
ofectamine 2000 (Invitrogen, Waltham, MA) in a 1.9-cm2 well.
HEK293 cells with green fluorescence were voltage clamped at
room temperature 48 to 72 hours after transfection with Ax-
opatch 200B, Digidata 1440B, and pClamp software (all Axon
Instruments, Sunnyvale, CA). Extracellular solution was (in
mmol/L): NaCl 145, KCl 4, MgCl2 1, CaCl2 2, and HEPES 10,
pH 7.4 (NaOH). Patch electrodes were filled with pipette solu-
tion (in mmol/L): NaCl 5, CsCl 145, EGTA 10, and HEPES 10,
pH 7.3 (CsOH). Liquid junction potential was estimated at
24.4 mV and not corrected for. Currents were low-pass filtered
at 5 kHz and sampled at 50 kHz. Series resistance error was kept
below 5 mV. Data were analyzed and illustrated with pClamp,
Origin (OriginLab, Northampton, MA), and Excel (Microsoft,
Redmond, WA) software. The voltage protocols are described in
the figure legends. The current- and conductance-voltage rela-
tionships were fitted with the Boltzmann equation: G 5 A 1 (B
2 A)/{1 1 exp[(V1/2 2 V)/Vslope)]}, where A and B are the
maximum and minimum amplitudes, V1/2 is the voltage where
amplitude is (A 2 B)/2, and Vslope is the slope factor. The time
course data of recovery from inactivation and of onset of fast
inactivation were fitted with single or double exponential func-
tions, respectively. Statistical comparisons were performed with
the Student t test.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the Institutional Review
Board of Tampere University Hospital. All participants provided
appropriate consent, and the study was conducted according to
the Helsinki Declaration.
RESULTS Clinical and genetic findings of the patients
with p.A1156T. In the patient cohort, 17 were female
and 12 were male. The age at onset of symptoms
ranged from 4 to 53 years (mean 28.7 years). How-
ever, only 3 patients reported an early-childhood
onset of muscle symptoms; the more typical age at
onset was between 20 and 40 years. The common
clinical features were exercise and cold-induced
muscle cramps, muscle stiffness, and myalgia. Sev-
eral patients also experienced muscle weakness or
fatigue during and shortly after exercise, although
without paralytic episodes (e.g., paralysis at rest after
exercise). Muscle strength was normal in all but 2
patients on clinical examination. CK level was slightly
increased in 1 patient (2.5 times the upper normal).
Muscle biopsies showed mild abnormalities, i.e., rare
highly atrophic fibers or increased internal nuclei.
However, the findings were considered normal in 7
patients. Clinical myotonia (grip, percussion, eyelid
myotonia) or typical paramyotonia (repeated action
myotonia) was not evident on clinical examination.
The diagnosis of fibromyalgia was very common
among the family members of the patients. Clinical
details of each patient are shown in table e-1.
All 29 patients were identified with the heterozy-
gous c.3466G.A p.A1156T mutation.8 Two unre-
lated patients, P16 and P18, were also carriers of the
recessive c.2680C.T p.R894X mutation in the
CLCN1 gene. Both had normal CLC-1 protein
expression as judged by immunohistochemical stain-
ing, indicating no additional defect in the correspond-
ing gene.11
Screening of the DM2-neg and fibromyalgia groups. No
mutations were observed in the fibromyalgia group.
In the DM2-neg group, one patient (P30) was
found to harbor the p.A1156T mutation. She had
exercise-induced myalgia and cramps starting at age
28. Clinical examination was normal, and there was
no electrophysiologic myotonia, but EMG showed
increased insertional activity with uncharacteristic
repetitive discharges. She had occasional elevated CK
levels (2 times the upper normal limit), and her
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muscle biopsy from gastrocnemius medialis muscle
was normal.
Muscle MRI. Two siblings in family 3 had mild degen-
erative changes in vastus lateralis muscles, although
muscle strength was normal on manual testing. One
patient (P22) had mild degenerative findings on
MRI in the left thigh muscles. She had had a fracture
of the left femur 10 years earlier due to fibrous dyspla-
sia of bone that might contribute to the imaging find-
ings and to the clinical finding of muscle weakness on
the left lower limb. The one patient from the DM2-
neg group who had the p.A1156T mutation in the
screening study showed normal muscle MRI findings
at the age of 30.
Electrophysiologic findings. EMG myotonic discharges
were detected in most but not all patients. EMG was
not studied in 5 symptomatic mutation carrier family
members of the probands. Sixteen patients had myo-
tonia on EMG at some point, but interestingly, in 6
of them, myotonic discharges disappeared on
repetitive examinations with more advanced age
(table 1). The rest of the patients showed increased
insertional activity only. Thus, none of the initial
EMG studies were completely normal. Fourteen pa-
tients underwent CMAP exercise test (Fournier pro-
tocol) with variable results. It was normal in 6
patients; 3 patients showed a 35% to 55% decrease
of CMAP amplitude after the short exercise; 4 pa-
tients had a 28% to 60% decrease after the long
exercise; and 2 patients had a 30% to 44% decrease
after cooling.
Functional studies. When expressed in HEK293 cells,
the p.A1156T channels activated normally (figure 2,
A–C). Fast inactivation of p.A1156T channel was
mildly attenuated compared to the wild-type chan-
nel: V1/2 was shifted ,3 mV to depolarized voltages
(p , 0.05) (figure 2D), and the recovery from inac-
tivation was accelerated 1.7-fold (p , 0.001) (figure
2E). No significant changes in the rate (figure 2F) or
completeness of the open-state inactivation were de-
tected (not shown). The voltage dependence of slow
Table 1 Electrophysiologic findings of patients with p.A1156T
Patient Myotonia on EMG CMAP exercise test
P1 (F1 II:2) No. Increased insertion activity, repetitive discharges Not done
P3 (F1 II:4) Yes, at age 40; increased insertion activity only at age 55 Normal, short exercise induces myotonic potentials
P4 (F1 III:3) Yes Long exercise: 60% decrease of CMAP amplitude
P5 (F1 III:5) No. Increased insertion activity Normal
P6 (F1 III:6) Yes, at ages 16 and 20; increased insertion activity only at age 30 Normal (at age 30)
P8 (F2 II:5) Yes. Myotonia increased by cooling Not done
P9 (F2 III:1) Yes, at first study. Increased insertion activity only at age 49 Short exercise: 35% decrease; cooling: 44% decrease
P12 (F3 II:1) No. Increased insertion activity, repetitive discharges Normal
P13 (F3 II:2) No. Increased insertion activity, repetitive discharges Cooling: 30% decrease of CMAP amplitude
P14 (F4 II:2) Yes Not done
P16 Yes Normal
P17 Yes Not done
P18 Yes Short exercise: 35% decrease of CMAP amplitude
P19 No. Increased insertion activity Not done
P20 Yes Normal
P21 Yes Not done
P22 No. Increased insertion activity Not done
P23 Yes Long exercise: 31% decrease of CMAP amplitude
P24 No. Increased insertion activity, repetitive discharges Not done
P25 Yes, at first study. Increased insertion activity, repetitive discharges at age 58 Long exercise: 28% decrease of CMAP amplitude
P26 Yes, at first study. Increased insertion activity only at age 40 Short exercise: 55% decrease of CMAP amplitude
P27 No. Increased insertion activity Not done
P28 Yes Not done
P29 Yes, at first study. No myotonia at age 18 Long exercise: decrease in duration of potentials
P30 (DM2-neg) No. Increased insertion activity, repetitive discharges Not done
Abbreviations: CMAP 5 compound muscle action potentials; DM2 5 myotonic dystrophy type 2.
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Figure 2 Functional characterization of p.A1156T channel
(A) Representative current traces of wild-type and p.A1156T channels in response to test voltages ranging from 260 to
50 mV. Scale bars are 1 millisecond (x-axis) and 20 pA/pF (y-axis). Dashed lines indicate 0 current level. Voltage protocol for
voltage steps ranging from2150 to 50 mV is shown in inset. (B) Peak current amplitude in response to test voltages ranging
from 2150 to 50 mV in 10-mV increments is plotted against the test voltage for wild-type (solid circles) (n 5 18) and
p.A1156T (open squares) (n5 11) channels. (C) Voltage dependence of activation was estimated by plotting the conductance
[peak current/(test voltage2 reversal voltage)] against the test voltage for wild-type (solid circles) (V1/25220.36 0.7mV, n5
18) and p.A1156T (open squares) (V1/2 5 220.4 6 0.7 mV, n 5 11) channels. Individual data were normalized to maximum
and minimum amplitude of the Boltzmann fit and averaged. Solid lines represent the fit of the Boltzmann equation to the mean
data. (D) Voltage dependence of fast inactivation was estimated by plotting the peak tail current amplitude at 210 mV after
150-millisecond prepulse voltage steps ranging from2150 to0mV in10-mV increments against the prepulse voltage for wild
type (solid circles) (V1/25 266.26 0.7 mV, n5 18) and p.A1156T (open squares) (V1/25 263.56 1.0 mV, n5 11) channels.
Continued
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inactivation of p.A1156T channel was shifted 7 mV
to the hyperpolarized direction compared to the wild-
type channel (figure 2G) (p , 0.001).
DISCUSSION Our larger cohort of 30 patients carry-
ing the c.3466G.A p.A1156T mutation in the
SCN4A gene showed a consistent phenotype of pre-
dominant myalgia, muscle stiffness, and exercise
cramps without signs of clinical myotonia, paramyo-
tonia, or periodic paralyses. This also explains the
incomplete penetrance of myotonia reported in the
original family.8 Predominant myalgic phenotype ex-
pands the spectrum of SCN4A channelopathies and
interferes with the very large group of patients with
myalgia. Relatively modest gain in the function of
p.A1156T channel in whole-cell patch clamp stud-
ies may explain the absence of clinical myotonia.
Mutations in SCN4A gene typically produce sev-
eral different subtypes of skeletal muscle disorders con-
sisting mainly of clinical and electrophysiologic
myotonia or periodic paralyses. Different mutations
usually account for different ion channel characteristics
and phenotypes, although some of the mutations can
cause several phenotypes.2 The c.3466G.A p.A1156T
mutation has been reported with most of the SCN4A
manifestations: PMC, HyperPP, and pure myoto-
nia.8,13 The articles describing these patients did not
report myalgia as part of the clinical manifestation.
The main symptom in the first reported family with
the p.A1156T mutation was HyperPP, which none of
our patients demonstrated.8 Of 2 unrelated Korean
patients identified with c.3466G.A p.A1156T, 1
patients had myotonia with a warm-up phenomenon
resembling chloride channel myotonia, and the other
had HyperPP. Myotonic discharges were present on
EMG in both patients.13 The clinical presentation in
our larger patient series was not consistent with peri-
odic paralysis or paramyotonia, although many patients
had experienced worsening of the symptoms in cold
and some during repetitive exercise resembling para-
doxical myotonia. Two patients with an additional het-
erozygous CLCN1mutation did not differ largely from
the rest of the patients, although heterozygous CLCN1
mutations have been found to modulate phenotype in
sodium channel myotonia.14
The findings in electrophysiologic studies, both reg-
ular and CMAP exercise tests, were variable and did
not directly show typical sodium channel patterns,
nor were they clearly compatible with clinical symp-
toms as previously suggested.9,10,15 Although most of
the studied patients had myotonia on EMG at some
point, they did not show clinical myotonia, and fur-
thermore, myotonic discharges could disappear later in
life, as was observed in 6 of our patients. The findings
on the CMAP exercise test were normal in 43% of the
patients studied and inconsistent in the rest.
Our functional data are consistent with previous re-
ports showing attenuated fast inactivation of p.
A1156T channels.16–18 The p.A1156T channels
showed a mild shift in the voltage dependence of fast
inactivation and acceleration of recovery from fast inac-
tivation. However, in contrast to the previous reports,
we did not find defects in the time course of open-state
fast inactivation or signs of persistent late currents.
While the functional expression reports on A1156T
show some discrepancies, defective fast inactivation,
in particular accelerated recovery from inactivation, is
a consistent feature.16–18 The gain of function caused
by attenuated inactivation is consistent with myotonic
phenotype. The relatively modest shift in the voltage
dependence of fast inactivation and acceleration in the
rate of recovery from inactivation and the absence of
defects in the open-state inactivation may underlie the
milder clinical phenotype in which clinical myotonia is
not the predominant presentation. In addition, it has
been suggested that attenuated slow inactivation is
common for SCN4A variants associated with periodic
paralysis. The slow inactivation of p.A1156T channel
Figure 2 legend, continued:
The voltage protocol is shown on the right. Individual data were normalized to maximum and minimum values of the
Boltzmann equation and averaged. Solid lines represent the fit of the Boltzmann equation to the mean data. (E) To estimate
the time course of recovery from the inactivation, the current in response to a second voltage pulse to 0 mV (P2) divided by
the current in response to the first 10-millisecond pulse to 0 mV (P1) is plotted against the duration of the recovery step
at 280 mV between the 2 pulses. Data are shown for wild-type (solid circles) (t 5 6.5 6 0.4 milliseconds, n 5 16) and
p.A1156T (open squares) (t5 3.86 0.3 milliseconds, n5 10) channels. The voltage protocol is shown in the inset. The solid
lines represent the fit of exponential function to the mean data. (F) Time course of open-state inactivation was estimated by
fitting a double exponential function to the current decay between 90% of peak current amplitude and the current baseline.
Time constant (t) of inactivation at voltages ranging from 220 to 20 mV is shown for wild type (solid circles) (n 5 18) and
p.A1156T (open squares) (n 5 11) channels. Voltage protocol was as in panel (A). Only the time constant of the fast
component that carries z95% of the amplitude of the inactivating current is shown. (G) Voltage dependence of slow
inactivation was studied by plotting the peak tail current amplitude at210mV after a 10-second prepulse to voltage steps
ranging from2130 to 50mV in 10-mV increments against the prepulse voltage for wild-type (solid circles) (V1/25251.26
0.9 mV, n5 12) and p.A1156T (open squares) (V1/25258.36 1.0 mV, n5 7) channels. Between the prepulse and the test
pulse, the voltage was stepped to 2100 mV for 20 milliseconds to allow the channel to recover from fast inactivation. The
voltage protocol is shown in the inset. Individual data were normalized by dividing with maximum value of the Boltzmann
equation and averaged. Solid lines represent the fit of the Boltzmann equation to the mean data.
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was enhanced compared to the wild-type channel, con-
sistent with the absence of periodic paralysis in our
p.A1156T cohort.18
Myalgia is a very common symptom in the general
population, but it is only rarely caused by an under-
lying muscle disease. At present, no useful guidelines
exist on how to clarify the cause of myalgia.19 Painful
cramps or myalgia with myotonia have been reported
in a few families with other SCN4A mutations,20–23
but to the best of our knowledge, myalgia without
myotonic discharges on EMG has not been reported
before. Besides p.A1156T SCN4Amutation, DM2 is
an important disorder to be considered in differential
diagnostics of myalgic syndromes. In the early stages
of DM2, the symptoms resemble those of p.A1156T
because clinical or EMG myotonia also can be absent
in DM2.24,25 The age at onset of muscle symptoms
was earlier in our cohort than in typical cases of DM2.
Clearly, elevated CK levels, fixed muscle weakness, or
other myopathic signs on muscle histology, imaging,
or EMG suggest DM2 rather than milder form of
SCN4A disease. EMG seems to be a useful tool
because the findings were not completely normal in
any of our patients. However, the mildest change, i.e.,
increased insertional activity, can be easily overlooked
and not considered clinically relevant.
In the Exome Aggregation Consortium database,
the mutation c.3466G.A p.A1156T has been iden-
tified in 2 of 3,307 Finnish individuals. If this allele
frequency of the mutation is representative for the
whole population, there are some 3,000 individuals
carrying the mutation in Finland. Even with a lower
frequency and considering the usual adult onset of
symptoms, it can be estimated that some 1,000 pa-
tients in Finland may have myalgia, stiffness, and
cramps caused by this mutation.
Milder mutations in SCN4A gene may thus
underlie myalgic syndromes, especially if the patient
has cold-induced worsening of the symptoms and
increased insertional activity with or without myo-
tonic discharges on EMG.
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